Henry Gosebruch, Neumora CEO
July 18, 2023 06:30 AM EDT
People
R&D

Neumo­ra goes big with three PhI­II de­pres­sion stud­ies, new CEO from Ab­b­Vie’s C-suite

Kyle LaHucik

Senior Reporter

The wheels are rolling fast at Neumo­ra as the “Re­al­ly Big Neu­ro­science Com­pa­ny” nears three Phase III tri­als for its in­ves­ti­ga­tion­al de­pres­sion drug, read­ies …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

A service from the Financial Times